Aug 12, 2026 04:05PM
Jul 28, 2026 07:00AM
Jul 28, 2026 07:00AM
Mar 24, 2026 08:01AM
Mar 24, 2026 08:00AM
Nov 25, 2025 08:00AM
May 12, 2025 04:11PM Atea Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update
May 7, 2025 07:00AM
May 7, 2025 07:00AM
Apr 23, 2025 07:00AM
Apr 9, 2025 07:00AM
Mar 19, 2025 07:00AM
Mar 6, 2025 04:05PM
Dec 4, 2024 07:00AM Atea Pharmaceuticals (AVIR) Announces Positive Results from Phase 2 Study of Bemnifosbuvir and Ruzasvir Regimen for Treatment of Hepatitis C Virus
Dec 4, 2024 07:00AM
Nov 7, 2024 04:05PM
Aug 28, 2024 07:01AM
Aug 28, 2024 07:00AM
Aug 7, 2024 04:05PM
May 14, 2024 04:05PM
Mar 27, 2024 07:00AM Atea Pharmaceuticals Completes Patient Enrollment in Global Phase 3 SUNRISE-3 Trial Evaluating Oral Antiviral Bemnifosbuvir for COVID-19 in High-Risk Patients
Feb 28, 2024 04:05PM
Nov 8, 2023 04:05PM
Aug 8, 2023 04:05PM
May 8, 2023 04:05PM
Apr 25, 2023 07:02AM
Apr 25, 2023 07:00AM
Nov 29, 2022 07:00AM Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19
Nov 3, 2022 07:01AM
Nov 3, 2022 07:00AM
Sep 26, 2022 07:01AM
Sep 26, 2022 07:00AM
Sep 13, 2022 07:03AM
Sep 13, 2022 07:00AM
Aug 8, 2022 04:05PM Atea Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Business Update
May 10, 2022 06:30AM
Nov 17, 2021 09:24AM
Nov 16, 2021 05:43PM
Jan 19, 2021 07:00AM
Jan 31, 2018 09:00AM
Jan 24, 2018 09:00AM
Aug 31, 2017 04:01PM Aviragen Therapeutics Reports Fourth Quarter and Fiscal Year 2017 Financial Results
May 4, 2017 07:00AM
Apr 4, 2017 06:02AM
Apr 4, 2017 06:00AM
Feb 13, 2017 04:02PM
Feb 13, 2017 04:01PM
Feb 2, 2017 04:01PM
Feb 1, 2017 04:32PM Aviragen Therapeutics' (AVIR) Phase 2a RSV Challenge Study of BTA585 Misses Primary Endpoint
Feb 1, 2017 04:30PM

330,005 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All